In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at SOPHiA GENETICS SA (NASDAQ:SOPH) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

10 Best Cheap AI Medicine Stocks to Buy Now

9. SOPHiA GENETICS SA (NASDAQ:SOPH)

SOPHiA GENETICS SA (NASDAQ: SOPH) takes ninth place as one of the most AI-focused precision medicine companies in the public market.

The company operates a cloud-based platform that analyzes genomic and multimodal healthcare information. Hospitals, clinical laboratories and pharmaceutical companies use the platform to interpret complex medical data, identify genetic characteristics and support more personalized treatment decisions.

This is an area in which artificial intelligence can provide practical value. Modern sequencing systems can generate enormous amounts of genomic data, but producing the data is only the beginning. Healthcare institutions still need software that can analyze the information and convert it into clinically useful insights.

Second-quarter 2026 revenue increased 27% year over year to approximately $23.3 million. Analysis volume climbed 22% to a quarterly record of around 115,000, while the company signed 24 new customers.

Growth was especially strong in important expansion markets. U.S. revenue increased 64%, while liquid-biopsy revenue jumped 80%. The company also reported 993 customers across 75 countries, including relationships with several leading global cancer centers.

Its recurring, volume-based business model is another positive. Annualized revenue churn remained below 1%, while net dollar retention reached 117%. Those figures suggest that existing customers are not only staying on the platform but are also expanding their usage.

The financial picture is less convincing. The company remains unprofitable and reported an adjusted EBITDA loss of approximately $8.8 million during the second quarter. That was an improvement from a $12 million loss one year earlier, but the path toward sustainable profitability remains unfinished.

SOPHiA GENETICS SA (NASDAQ: SOPH) deserves attention because artificial intelligence is not simply a marketing label attached to an unrelated healthcare operation. AI has been central to the platform since its founding. Nevertheless, its relatively small revenue base and continuing losses make it one of the riskier AI healthcare stocks in this ranking.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.